Show your support for this innovation. Tweet it. Like it on Facebook. Leave a comment.
The following SMART 100 profile and the information it contains is a duplication of content submitted by the applicant during the entry process. As a function of entry, applicants were required to declare that all details are factually correct, do not infringe on another’s intellectual property and are not unlawful, threatening, defamatory, invasive of privacy, obscene, or otherwise objectionable. Some profiles have been edited for reasons of space and clarity. More about the SMART 100.
ENEdropp (NSW)
This innovation initially came to life when…
The need for this innovation was born after I took my grandparents to the eye hospital for cataracts surgery. As we all get old, cataracts is an issue most of us will see. Applying the correct prescribed drop dosage is important for the healing process. After interviewing some patients at the hospital and observing my grandparents, I found that there were numerous hurdles to applying a compliant dosage of eye drop with the conventional packaging. I then set out to design ENEdropp.
WHAT & HOW
The purpose of this innovation is to…
Help users apply drops into their eyes with ease. By creating ease of use, we can minimise the frustration of not being able to accurately apply drops. ENEdropp incorporates anti-contamination features which is important for sensitive organs like the eye.
It does this by…
Redesigning the packaging of the eye dropper cap and bottle. “An easily accessible solution which is suitable for most eye care users helps users guide and distill eye drop solutions into their eyes.”
PURPOSE & BENEFITS
This innovation improves on what came before because…
Existing technology is large, cumbersome and flimsy. Our innovation is unique. By incorporating patented features into the design of the packaging it greatly improves likelihood and ease of use and in turn increases effectiveness of the medical solution.
Its various benefits to the customer/end-user include…
- Assisting the elderly with minimal hand-eye coordination and the visually impaired (direct target market). Apply compliant dosages of medical solutions for the eyes.
- Increasing the effectiveness of the medical solution.
- Incorporating into the packaging increases ease of use.
COMPETITIVE LANDSCAPE
In the past, this problem was solved by…
Additional eye dropper aide attachments, which would be placed over or around the eye dropper bottles. The devices currently available would allow users to rest the attachments around the eye area to stop any shaky hands.
Its predecessors/competitors include…
Its competing technologies do not include the ability to have the patented features embedded into the packaging itself.
TARGET MARKET
It is made for…
It is made for the worldwide eye drop market. The targeted audience is anyone who self-administers eye drops into their eyes. The global market for ENEdropp will consist of the pharmaceutical eye drop, eye moisturising, eye infection, allergy, and vitamin, contact lens and niche eye care markets. In the worldwide market, there are approximately over 285 million visually impaired patients. The need for repeat dosage will multiply the need for ENEdropp.
DISTRIBUTION STRATEGY
It is available for sale through…
From a consumer perspective ENEdropp will be available through prescription and over-the-counter sales. From a corporate perspective ENEdropp will be distributed through a licensing arrangement with a packaging manufacturer or a pharmaceutical company with an ophthalmic focus.
Our marketing strategy is to…
Our marketing strategy is to bring on strategic investors in the ophthalmic or pharmaceutical/biotech industry to commercialise ENEdropp. Licensing the design to a packaging manufacturer or large ophthalmic company is the goal. Pharmaceutical is the end-goal.
SHARE THE LOVE
You can show your support for this outstanding Australian innovation in three ways:
- Tweet it: Top left of each page
- Trigger a Reaction: Facebook ‘Like’, etc.
- Leave a Comment: Anonymous comments excluded.
More about the READERS’ CHOICE INDEX.
